# Chronobiological Basis of Depression during the Menopause Transition

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2024 · $777,135

## Abstract

Project Summary/Abstract
The 2017 Nobel Prize in Physiology and Medicine was awarded for work on circadian rhythm (CR) regulation.
Now the challenge is to translate these basic science principles to clinical populations. Significant hormonal
changes during the perimenopause (P-M) may disrupt CRs, manifesting as mood, sleep and activity
dysfunction, increasing depressive illness risk. In this proposal we aim to test further a hypothesis of CR
dysregulation in P-M mood and sleep dysfunction by administering critically-timed sleep + light interventions
(SLI) designed to target and correct CR misalignment, and thereby improve mood and sleep. By this approach,
ultimately we aim to optimize P-M health and prevent disease and disability. Hypotheses are: 1) SLI which
phase-advance (shift earlier) vs phase-delay (shift later) CRs, best measured by melatonin, will ameliorate
mood and sleep dysfunction, and 2) A corrective phase-shift in the primary biological target, melatonin timing,
will be a significant mediator of improved function. In P-M depressed participants (DP) vs normal controls (NC),
we recently reported increased plasma melatonin secretion and delayed morning melatonin offset associated
with mood and sleep disturbances; correcting the phase-delayed melatonin CR with critically-timed sleep
(wake therapy) + light interventions improved mood and sleep within 1-2 weeks, correlating significantly with
melatonin phase-advance. To confirm target engagement and intervention mechanisms, in P-M women we will
compare 1) an Active Phase-Advance Intervention (PAI): phase-advanced restricted sleep (sleep 9pm-1am)
for 1 night, followed by 2 weeks of phase-advancing morning (AM) bright white light (BWL) for 30 min/day
starting within 30 min of wake time, vs 2) a Control Phase-Delay Intervention (PDI): phase-delayed restricted
sleep (sleep 3-7am) for 1 night, followed by 2 weeks of phase-delaying evening (PM) BWL for 30 min/day
ending 30 min before bedtime. In pilot data, we found relatively inert effects of Control PDI on melatonin and
nonsignificant (non-worsening) effects on mood and sleep. Combining SLI hastens, potentiates and maintains
their beneficial effects. In a randomized parallel design in 100 P-M women with mood and sleep/activity
dysfunction, we will administer either PAI or PDI at home (to enhance ecological validity), assessing effects on
psychometric measures, urinary 6-sulfatoxy-melatonin (6-SMT) and actigraphy sleep/activity. This innovative
combination of SLI identifies novel targets for health and disease prevention, and addresses an unmet
therapeutic need in P-M women. It extends to the P-M our investigations of CR dysregulation and its
restoration with SLI in other mood and sleep disorders associated with hormonal change in premenstrual and
peripartum depression. This approach potentially offers a safe, efficacious, rapid-acting, well-tolerated, non-
pharmacological, sustainable, affordable, home, and thus effective, intervention that ca...

## Key facts

- **NIH application ID:** 10881007
- **Project number:** 1R01MH134120-01A1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN DIEGO
- **Principal Investigator:** BARBARA L PARRY
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $777,135
- **Award type:** 1
- **Project period:** 2024-05-09 → 2029-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10881007

## Citation

> US National Institutes of Health, RePORTER application 10881007, Chronobiological Basis of Depression during the Menopause Transition (1R01MH134120-01A1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10881007. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*